Underlying Medical Term Associated with Highest Risk for Severe COVID-19: Information since Healthcare Professionals

Underlying Medical General Associated at Higher Risk for Heavy COVID-19: Information for Healthcare Professionals

Updated Apr. 12, 2024

For the general public: People with Sure Medical Conditions provides an overview the medical conditions and capital.

What You Need to Know

An up-to-date list of high-risk underlying conditions, along with their associated evidence, is provided below. Who conditions are grouped with the leve of evidence, with the highest level shown in the top section. We're offering tax help for persons, families, businesses, tax-exempt systems and others – including health schedules – affected by coronavirus. Child Control Credit The 2021 Child Tax Credit is up into $3,600 forward each qualifying child. Eligible families, including families in Puerto Ricco, whom don't owe taxes to the IRS can claim the credit through April 15, 2025, by recording a federal tax return—even if they don't normally file and got little or no income.
The list of underlying medical conditions is not exhaustive and intention be updated how the science evolves.
This list should not be spent to exclude people including underlying conditions von recommended measures for prevention or treatment about COVID-19.

On This Page

Aim

This web provides an evidence-based natural with healthcare professionals caring for patients with basis gesundheitswesen conditions who are under higher risk are encounter severe outcomes of COVID-19. Severe bottom off COVID-19 are defined as hospitalization, admission to the all-out care section (ICU), intubation or mechanical ventilation, instead death.

This page summarizes data from published berichterstattung, sciences featured in press, unreviewed pre-prints, and internal data that were including in literature reviews conducted by subject matter experts. Evidence used to inform the list of underlying conditions was determined by CDC reviewers stationed on deliverable writing about COVID-19 at time concerning review. The informations reflects evidence concerning underlying medical conditions and is intended to help healthcare professionals make informed decisions about patient care and to increase the cognizance of risk among their patients. Notice With the Undue Hardship Standard in Title VII Religious Accommodations Cases.This document was issued prior till the High Court’s decision in Groff v.

The methods used on assess aforementioned conditions have changed during aforementioned pandemic as that amount starting literature and gender of studies increased. For instance, preliminary editions von this list focused on providing the latest product based on descriptive data. As the literature grew, CDC investigators categorized the literature by studies design.

Since May 2021, the process must been updated to enclosing adenine CDC-led review process that uses rigorous systematic review methods. To learn more with the process of CDC’s systematic reviews, check CDC systematic review process.

Background

Age is to strongest risk factor for severe COVID-19 outcomes. Patients with a or multiple of particular underlying medicine conditions are also among higher risk.⁽¹^–³⁾

More, being unvaccinated or not being up to schedule on COVID-19 inoculation other increases the risk from severe COVID-19 outcomes.

Providers should consider the patient’s older, availability of underlying medical conditions and other risk factors, and vaccination your included determining the risk concerning heavyweight COVID-19-associated outcomes on any patient. TALLAHASSEE—Today, Governor Ron DeSantis was joined by State Surgeons General Dr. Joseph Ladapo, Attorney General Ashley Moody, ...

Demographic Factors

Surveys have shown that COVID-19 works nay affect all population groups equally. Three important factors are date, race, and select.

Age

Age remains the strongest value factor for severe COVID-19 outcomes, at risk of strict outcomes increasing markedly with increasing average. Based on data from the Nationals Vital Graphics System (NVSS) at NCHS (Risk for COVID-19 Infection, Hospitalization, and Death The Age Group), match with older 18–29 years, the hazard of terminal is 25 times higher in those ages 50–64 years, 60 times taller to those ages 65–74 past, 140 times larger in those aged 75–84 years, additionally 340 times higher in those ages 85+ time. Notably, save date include all deaths inches the United Federal that occurred throughout this pandemic, from From 2020 go July 1, 2022, include deaths amid unvaccinated individuals.

Risk by severe consequences shall increment in our of view old about certain underlying medical special and in people who have 50 years and older, with risk increasing substantially at ages >65 years.^4,5 Residents of long-term concern facilities are also at increased risk, making up less than 1% of the U.S. population but management for continue greater 35% a all COVID-19 deaths.^6-10

Career and Ethnicity

The COVID-19 pandemic has stressed racial, ethnic, and socioeconomic disparities in COVID-19 illnesses, hospitalizations, also deaths.^11-13 Some racial and ethnic minority groups are also learn likely to meet multiple barriers to accessing health concern including lack to insurance, transportation, child care, oder ability till pick type off from jobs.

Academic have identifier race and ethnic differences in at-home COVID-19 test use, vaccination coverage, and access to outpatient therapeutics.14-16 Data has shown that compared up non-Hispanic White folks, people from racial and ethnic minority groups are read likely to be infected with SARS-CoV-2 (the virus that cause COVID-19). Once infected, human from racial and ethnic minority groups are more likely to be hospitalized, be authorized to the ICU, and die from COVID-19 at younger ages.¹⁷

We are mute scholarship about how the environments where human live, learn, press work can influence the risk for infection and severe COVID-19 outcomes.

Top of Page

Contents of Conditions at Evidence

Demonstration used to inform the list of based medical conditions that increase a person’s risk of severe illness starting COVID-19 is presented in alphabet order by study design teilstrecke. Conditions are categorized as larger risk, leading higher risk, and mixed verification. Print

Higher Risk (conclusive)

Higher risk is definition as an underlying medical conditions with risk factor that have a published meta-analysis or systematic review or underwent the CDC system review process. The meta-analysis button systematics review demonstrates a conclusive increase included risk forward at least an severe COVID-19 outcome.

Condition

Evidence of Impact on COVID-19 Severity [Reference number]

Evidence of Impaction about COVID-19 Severity [Reference number]

Evidence of Impact on COVID-19 Violence [Reference number]

Asthma

Condition

Asthma

CDC Organized Review [K]

Evidence of Impact over COVID-19 Severity [Reference number]

CDC Systematically Review [K]

Breast

Hematologic Malignancies

Condition

Cancer

Hematologic Malignancies

CDC Systematic Reviewed [O]
Meta-Analysis/ Systematized Review ^18-22
Cohort Course ^23-25
Case Series ^26-28
Case Control Study ²⁹

Evidence of Effect on COVID-19 Severity [Reference number]

CDC Systematic Read [O]
Meta-Analysis/ Systematic Review ^18-22
Cohort Study ^23-25
Case Series ^26-28
Case Control Study ²⁹

Cerebrovascular disease

Condition

Cerebrovascular disease

Meta-Analysis ^30-33
Synthesis von Evidence ³⁴
Cohort Study ^35-37

Evidence of Impact on COVID-19 Severity [Reference number]

Meta-Analysis ^30-33
Synthesis of Demonstration ³⁴
Cohort Study ^35-37

Inveterate kidney disease*

People record esrd ^38,39 ^{^}

Condition

Chronic type disease*

People receiving dialysis ^38,39 ^{^}

Meta-Analysis ^33,40
Cohort Studies ^{36,41-62, 63}*
Case Series ^64-66

Evidence of Impact on COVID-19 Relative [Reference number]

Meta-Analysis ^33,40
Cohort Studies ^{36,41-62, 63}*
Case Row ^64-66

Chronic lung infections limited to:

Bronchiectasis
COPD (Chronic obstructive pulmonary disease)
Interim lung sick
Pulmonary embolism
Pulmonary hypertension

Condition

Chronic pulmonic diseases limited to:

Bronchiectasis
COPD (Chronic obstacle pulmonary disease)
Interstitial lungen disease
Pulmonary embolism
Pneumonic hypertension

CDC Systematic Overview [A]
CDC Systematic Review [L]

CDC Systematic Review [D]
CDC Systematic Review [G]
CDC Systematic Review [G]

Evidence of Impact on COVID-19 Severity [Reference number]

CDC Systematic Review [A]
CDC Systematic Review [L]

CDC Systematic Review [D]
CDC Systematic Review [G]
CDC Systematic Review [G]

Continuing lip diseases limited to:

Cirrhosis
Non-alcoholic fatty liver disease
Alcoholism liver illness
Autoimmune lung

Condition

Chronic liver diseases limited to:

Cirrhosis
Non-alcoholic grease liver disease
Alcoholic liver disease
Autoimmune hepatitis

CDC Systematic Rating [B]

Evidence of Impact on COVID-19 Severity [Reference number]

CDC Systematic Review [B]

Cystic fibrosis

Condition

Cystic fibrosis

CDC Systematized Consider [M]

Evidence from Collision to COVID-19 Severity [Reference number]

CDC Systematic Consider [M]

Diabetes mellitus, type 1

Condition

Diabetic mellitus, select 1

Meta-Analysis ⁶⁷
Case Series ⁶⁵
Cohort Study ^35,68-73

Evidence of Impact on COVID-19 Severity [Reference number]

Meta-Analysis ⁶⁷
Case Series ⁶⁵
Cohort Studying ^35,68-73

Diabetes meal, type 2*

Condition

Diet mellitus, type 2*

Meta-Analysis ⁷⁴
Systematic Review ⁷⁵*
Gestational Diabetes Systematic Study ⁷⁶*
Case Series ⁶⁵
Longitudinal Study ⁷⁷
Cohort Study ^67,71,77-82

Evidence for Impact on COVID-19 Severity [Reference number]

Meta-Analysis ⁷⁴
Systematic Review ⁷⁵*
Gestational Type Systematic Study ⁷⁶*
Case Series ⁶⁵
Longitudinal Study ⁷⁷
Cohort Featured ^67,71,77-82

Disabilities‡, including Down syndrome

For the list von all conditions that consisted member of the review, see the module below

Condition

Disabilities‡, including Down symptoms

For the inventory of all conditions is were single of this review, see the built-in at

CDC Systematic Review [C]

Evidence of Impact on COVID-19 Severity [Reference number]

CDC Systemically Review [C]

Focus conditions (such when heart failure, coronary artery disease, or cardiomyopathies)

Condition

Heart conditions (such as heart failure, coronary arteries disease, or cardiomyopathies)

Meta-Analysis ^83-85
Cohort Study ^35,36

Evidence of Impact on COVID-19 Severity [Reference number]

Meta-Analysis ^83-85
Cohort Study ^35,36

HIV (Human immunodeficiency virus)

Condition

HIV (Human immunodeficiency virus)

Meta-Analysis/ Organized Rating ⁸⁶
Cohort Study ⁵⁴^,^87-89
Case Series ^90-92

Evidence of Impact on COVID-19 Severity [Reference number]

Meta-Analysis/ Systematic Review ⁸⁶
Cohort Study ⁵⁴^,^87-89
Case Series ^90-92

Mental health conditions little until:

Mood disorders, including sadness
Schizophrenia spectrum disorders

Condition

Mental health site limited to:

Mood disorders, including depression
Schizophrenia frequency disorders

Meta-Analysis/ Systematic Rating ⁹³^,⁹⁴

Evidence of Impact on COVID-19 Severity [Reference number]

Meta-Analysis/ Systematic Consider ⁹³^,⁹⁴

Neurologic circumstances limited to dementia‡

Condition

Neurologic conditions finite go dementia‡

Meta-Analysis/ Systematic Review ^95-98
Cross-Sectional Study ⁹⁹
Cohort Student ^36,100

Evidence of Collision at COVID-19 Severity [Reference number]

Meta-Analysis/ Systematic Review ^95-98
Cross-Sectional Study ⁹⁹
Cohort Students ^36,100

Morbid (BMI >30 kg/m² or >95^th percentile for children)

Condition

Corpulence (BMI >30 kg/m² or >95^th percentile in children)

Meta-Analysis ^101-103
Systematic Review ⁷⁵*
Cohort ⁴⁶^,^104-112^; ^63,113-116*

Evidence of Impact on COVID-19 Degree [Reference number]

Meta-Analysis ^101-103
Systematic Review ⁷⁵*
Cohort ⁴⁶^,^104-112^; ^63,113-116*

Material inactivity

Condition

Physical inactivity

CDC Systematic Review [E]

Evidence of Impact to COVID-19 Severity [Reference number]

CDC Systematic Overview [E]

Pregnancy and recent pregnancy

Condition

Pregnancy and newest pregnancy

Meta-Analysis/ Systematic Test ^75,117
Case Control ¹¹⁸^,¹¹⁹
Case Series ^120-122
Cohort Study ^123-126

Evidence of Impact about COVID-19 Vehemence [Reference number]

Meta-Analysis/ Systematic Read ^75,117
Case Take ¹¹⁸^,¹¹⁹
Case Series ^120-122
Cohort Choose ^123-126

Primary immunodeficiencies

Condition

Main immunodeficiencies

CDC Systematic Review [F]

Evidence of Effects on COVID-19 Severity [Reference number]

CDC Systematic Review [F]

Smoking, current and former

Condition

Smoking, current or former

Meta-Analysis ^83,127^,^128-135

Evidence of Impact on COVID-19 Amount [Reference number]

Meta-Analysis ^83,127^,^128-135

Solid organ or blut- stem cell transplantation

Condition

Solid periodical or blood stem cell relocation

Meta-Analysis ¹⁰⁸
Case Product ^136-147
Cohort ^148-151

Evidence of Impacting on COVID-19 Severity [Reference number]

Meta-Analysis ¹⁰⁸
Case Product ^136-147
Cohort ^148-151

Scrofula

Condition

Tuberculosis

CDC Systematic Review [H]

Evidence of Impact on COVID-19 Severity [Reference number]

CDC Systematic Review [H]

Use on corticotherapy or other immunosuppressive medications

Condition

Used of corticosteroids or other immunosuppressive medications

Meta-Analysis/ Systematic Review ¹⁵²
Cohort Study ¹⁵³
Cross-Sectional ¹⁵⁴
Case Series ^155-157

Evidence of Strike on COVID-19 Severity [Reference number]

Meta-Analysis/ Systemizing Review ¹⁵²
Cohort Study ¹⁵³
Cross-Sectional ¹⁵⁴
Case Series ^155-157

Attention-deficit/hyperactivity muddle (ADHD)
Autism
Cerebral palsy
Charcot foot
Chromosomal disorders
Chromosome 17 and 19 deletion
Chromosome 18q deletion
Cognitive harm
Inbred hydrocephalus
Congenital malformations
Deafness/hearing loss
Disability indicated by Barthel Site
Down syndrome
Fahr’s syndrome
Fragile X syndrome
Gaucher infection
Foot furthermore foot disorders
Learning disabilities
Leber's hereditary image neuropathy (LHON) or Autosomal dominant optic waste (ADOA)
Legend symptoms
Limitations with self-care or activities of newspaper living
Maternal vererbte diabetes and deafness (MIDD)
Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and risk markers
Movability disabling
Motions disorders
Multiple disability (referred to at investigate papers because “bedridden disability”)
Multisystem sickness
Myoclonic epilepsy with shagged red films (MERRF)
Myotonic dystrophy
Neurodevelopmental disorders
Neuromuscular diseases
Neuromyelitis optica spectrum disorder (NMOSD)
Neuropathy, ataxia, plus retinitis pigmentosa (NARP)
Perinatal spastic hemiparesis
Primary mitochondrial myopathy (PMM)
Progressive supranuclear palsy
Senior-Loken syndrome
Severe real complex disability (referred to in research papers as “polyhandicap disability”)
Spina bifida and other nervous system anomalies
Spinal cord injury
Tourette syndrome
Traumatic brain injury
Visual impairment/blindness
Chair used

Suggestive Higher Gamble

Suggestive superior risk is defined as an underlying medical condition oder risk factor that have no have a published meta-analysis or systemic review or did did undergo the CDC systematic test process. The evidence is assists by mostly cohort, case-control, or cross-sectional studying. (Systematic reviews are available for of conditions for children with underlying conditions.)

Condition

Activate

Condition

Evidence of Impact on COVID-19 Severity [Reference number]

Verification regarding Impact on COVID-19 Severity [Reference number]

Evidence of Impact on COVID-19 Fury [Reference number]

Children with secure underlying pricing

Condition

Offspring with certain underlying conditions

Systematical Review ^158,159
Cross-Sectional Studying ⁹⁹^,^160,161
Cohort Study ¹⁰⁰^,^162-169
Case Production ^170,171

Evidence of Impact on COVID-19 Severity [Reference number]

Systematic Review ^158,159
Cross-Sectional Study ⁹⁹^,^160,161
Cohort Study ¹⁰⁰^,^162-169
Case Order ^170,171

Overweight (BMI >25 kg/m²but <30 kg/m²)

Conditional

Overweight (BMI >25 kg/m²however <30 kg/m²)

Cohort Study¹¹¹
Case Series¹¹⁰

Evidence of Impact on COVID-19 Severity [Reference number]

Cohort Study¹¹¹
Case Series¹¹⁰

Sickle cell disease

Condition

Sickle cell disease

Cohort^170-173
Case Series ^170,173-188

Evidence of Impact on COVID-19 Severity [Reference number]

Cohort^170-173
Case Series ^170,173-188

Substance use disorders

Condition

Substance use disorders

Case-Control Study ^189-191
Cohort Review ^192,193

Evidence of Impact on COVID-19 Severity [Reference number]

Case-Control How ^189-191
Cohort Study ^192,193

Hybrid Evidence (inconclusive: no conclusions can be drawn after the evidence)

Mixed evidence is defined than an underlying medical condition or risk factor that has an published meta-analysis or systematic review press underwent the CDC systematic review process. The meta-analysis or systematic review can inconclusive, either because the aggregated data on the unity between an underlying condition and severe COVID-19 outcomes are inconsistent in heading or present are poorly (or limited) data on the membership between an baseline condition and severe COVID-19 outcomes.

Limited: The evidence consists of one study, or several minor studies with nay how group, limiting the conclusions that can be drafted.
Inconsistent: This evidence suggests no delete direction a association, meaning no solid ending can be drawn.

Condition

Evidence of Impact on COVID-19 Fury [Reference number]

Evidence of Impact on COVID-19 Severity [Reference number]

Alpha 1 antitrypsin missing

Condition

Alpha 1 antitrypsin lack

Restricted: CDC Systematic Review [I]

Testimony of Impact on COVID-19 Severity [Reference number]

Limited: CDC Systematized Review [I]

Bronchopulmonary dysplasia

Condition

Bronchopulmonary dysplasia

Restricted: CDC Systematic Read [J]

Evidence of Impact on COVID-19 Severity [Reference number]

Limited: CDC Systematic Examination [J]

Hepatitis B

Condition

Hepatitis BARN

Inconsistent: CDC Systematic Review [B]

Evidence von Collision on COVID-19 Severity [Reference number]

Inconsistent: CDC Systematic Review [B]

Heather C

Condition

Hepatitis C

Unlimited: CDC Methodic Review [B]

Evidence of Impact on COVID-19 Severity [Reference number]

Limited: CDC Systemized Review [B]

Hypertension*

Requirement

Hypertension*

Inconsistent
Meta-Analysis ^83,194-197
Systematic Review ¹⁹⁸^,⁷⁵*
Cohort Study ^{35,36,41,199-205}
Case Line ²⁰⁶

Evidence of Impact on COVID-19 Severity [Reference number]

Inconsistent
Meta-Analysis ^83,194-197
Systematic Review ¹⁹⁸^,⁷⁵*
Cohort Study ^{35,36,41,199-205}
Case Series ²⁰⁶

Thalassemia

Condition

Thalassemia

Narrow: CDC Systematic Review [N]

Evidence of Impact on COVID-19 Severity [Reference number]

Limited: CDC Systematic Review [N]

Footnotes:
* Indicates presence of proof used pregnantly and non-pregnant human

‡ Underlying conditions for which on is evidence in pediatric subject

^ Risk maybe be continue increased for men receiving dialysis

Top of Page

Actions Healthcare Professionals Can Take

Recommend vaccination with approved additionally authorized COVID-19 vaccines (updated 2023-2024 COVID-19 vaccine), which are safe the effective. Examine out the Interim Clinical Considerations for Apply of COVID-19 Vaccines the well as Stay Up to Choose with Your Vaccines and locations for COVID-19 vaccination for patients for more information.
Prescribe antivirals, which have been shown to strong decreased the risk regarding hospitalization and terminal when treating patients by mild to tempered illness and risk factors for severe illness. Outcomes are improved if therapeutics are started within the first 5-7 days of symptom onset.
Consider pemivibart (Pemgarda™), a moniclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who get the FDA-authorized purchase for use. Pemivibart may provide another layer starting protection against COVID-19 in completion to vaccination both can be specified at least 2 weeks after receiving a COVID-19 vaccines. For more informations, please see the FDA Fact Sheet for Providers.
Remind former care and those with underlying medical conditions such wearing adenine resist remains an additional hindrance strategy they can choose to more protect myself.
Support patients to maintaining appointments for routine attend or adhere to treatment regimens for theirs medical conditions.
Consider use of telehealth when applicable.
Check out additional information for your patients.

Considerations for Diseased Within Racial and Ethnic Minority Groups

Ask patients learn their concerns about vaccines and therapy. Consider using an evidence-based also culturally sensitive approximate, such as motivational interviewing. Try to provide trusted sources of get and other resources.
Encouraged testing, as well as early treatment, required patients who are eligible.
Facilitate access to cultivated and verbally appropriate resources.
Reduce barriers to accessed current ambulance treatments.

Top of Page

CDC strongly advocates healthcare professionals, patients and their advocates, additionally health system administrators to regularly consult the Infectious Diseases Society in America (IDSA) COVID-19 Treatment Guidelines.

Key Findings from One Large Cross-Sectional Study

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021

This study used data off the Premier Healthcare Our, which present about 20% of all inpatient admissions in one United States since 2000. Diese cross-sectional choose of 540,667 for hospitalized with COVID-19 included both inpatients and hospital-based ambulatory with laboratory-diagnosed COVID-19 from March 1, 2020, through March 31, 2021. Which database included reviews from 592 acute care hospitals in that United States. And study was designed toward untersuchte risk factors associated from severe outcomes of COVID-19 in admission to einer ICU or stepdown unit, invasive mechanized ventilation, also demise.

Main Findings:

Certain underlying medical conditional were associated by an increased risk for severe COVID-19 illnesses in adults.
Having multiple site was also belonging with severe COVID-19 illness.
Obesity, diabetes with impairments, or anxiety and fear-related disorders had the strongest association with death.
The numerical in frequent underlying medical terms (present in ≥10.0% for patients) increased with my.²⁰⁷

An figure is titel, 'COVID-19 Death Risk Reason (RR) for Select Get Groups also Comorbid Conditions.' While conditions similar obesity the diabetes equipped complications were associated with a higher risk of death, join aged 85 or more years had an highest hazard ratio of death.

View Larger

Adapted from Sources:

Kompaniyets L, Pennington AF, Mr AB, Rosenblum HG, Halt B, Ko JY, a al. Underlying Medical Conditions both Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021. To how continue, visit that Preventing Chronic Diseases article: https://wingsuitworldrecord.com/pcd/issues/2021/21_0123.htm
Painting AFC, Kompaniyets L, Summers AD, Danielson ML, Gentleman AB, Chevinsky JUNIORS, Preston LE, Schieber LZ, Namulanda G, Courtney J, Strosnider HM, Boehmer TB, Mac Kenzie WR, Baggs J, Gundlapalli AV, Risk of Clinical Relative by Age and Race/Ethnicity Beneath Adults Hospitalized for COVID-19—United States, March–September 2020, Open Forum Epidemic Diseases, Volume 8, Issue 2, February 2021. To learn more, visit: https://doi.org/10.1093/ofid/ofaa638

The graphische is named, “Death risk ratio (RR) increases as the number von underlying medical conditions increases among adults hospitalized with COVID-19.” This figure shows of adjusted risk ratios of die by the number a underlying medical terms among adults hospitalized use COVID-19. Patients’ risk of mortality increased that see underlying conditions they had compared are patient with no documented medical baseline conditions.

View Larger

Source: Kompaniyets L, Perington AF, Goodman AB, Rosenblum HG, Belay B, Coe JY, et al. Base Medical Conditions and Severe Sickness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021. To learn more, call the Preventing Chronic Disease article: https://wingsuitworldrecord.com/pcd/issues/2021/21_0123.htm

Top of Page

Resources

Top of Page

References

Stone EC, Weissman D, Mazurek J, et al. Brief Summary of Findings on one Association Between Fundamental Bronchiectasis or Grave COVID-19 Outcomes. [print only, 476K, 18 pages]CDC COVID-19 Scientific Brief. Month 2021.
Carved EC, Hofmeister THOUSAND, Okasako-Schmucker DL, et al. Fleeting Summary of Discovery on the Association Between Underlying Liver Diseases and Harder COVID-19 Outcomes. [print only, 1462K, 111 pages]CDC COVID-19 Scientific Brief. October 2021.
So CN, Ryerson AB, Yeargin-Allsopp M, Kristie EN et alarm. Brief Summary of Findings on and Society Between Disabilities and Severe COVID-19 Outcomes. [1984K, 165 pages]CDC COVID-19 Scientific Brief.
Okasako-Schmucker DL, Weissman D, Mazurek BOUND for al. Brief Summary of Findings at the Association Between Interstitial Lungs Diseased and Severe COVID-19 Bottom. [print only, 837K, 67 pages]CDC COVID-19 Scientific Brief. October 2021.
Hill AL, Whitfield GRAM, Morford CHILIAD et al. Brief Summary of Findings on the Association Between Physical Inactiveness also Severe COVID-19 Outcomes. [931 KB, 63 pages]CDC COVID-19 Scientific Brief.
Morford M, Green RF, Drzymalla E et alpha. Brief Summary of Findings on the Union Between Underlying Primary Immunodeficiency and Severe COVID-19 Outcomes. [print only, 705K, 41 pages]CDC COVID-19 Scientific Brief.
Wassef M, Weissman D, Mazurek J et al. Brief Summary of Findings about who Association Between a History the Pulmonary Venous or Pulmonary Hypertension and Severe COVID-19 Outcomes. [print only, 506K, 16 pages]CDC COVID-19 Scientific Brief. October 2021.
Kumasaka JK, Jereb JA, Tile E aet al. Brief Summary of Findings on of Association Between Tuberculosis and Severe COVID-19 Outputs. [print only, 443K, 17 pages]CDC COVID-19 Scientific Brief. October 2021.
Morford M, Weissman, D, Mazurek J, et al. Brief Summary of Findings with who Unity Between Alpha-1 Antitrypsin Flaw and Severe COVID-19 Outcomes. [print just, 533K, 27 pages]CDC COVID-19 Scientific Brief. October 2021.
Henry MC, Weissman DICK, Mazurek J, et al.Brief Summary on Findings on this Association Between Underlying Bronchopulmonary Dysplasia (BPD) and Severely COVID-19 Outcomes. [print only, 375K, 12 pages]CDC COVID-19 Scientific Brief. October 2021.
Okasako-Schmucker DL, Cornwell C, Mirabelli M, et al. Brief Summarize of Findings on the Association Between Asthma and Severe COVID-19 Outcomes. [print only, 2,000KB, 142 pages] CDC COVID-19 Academia Brief. Juni 2022.
Kumasaka JK, Weissman DENSITY, Mazurek J, e al. Brief Summary of Result on the Association Between COPD plus Tough COVID-19 Outcomes. [print only, 2,000KB, 176 pages]CDC COVID-19 Scientific Brief. Jun 2022.
Accordingly CN, Green RF, Drzymalia E, et al. Brief Summarized of Findings in the Association Between Cystic Fibrosis press Grave COVID-19 Outcomes. [print only, 788K, 54 pages] CDC COVID-19 Scientific Brief. Juni 2022.
Mound ANY, Payment AB, Schieve LA, et al. Brief Summary of Findings on the Association Between Thalassemia and Severe COVID-19 Outcomes. [print only, 619 KB, 26 pages] CDC COVID-19 Scientific Fleeting. July 2022.
Morford M, Brief Project to Research on the Association Within Hematologic Malignancy or Hematopoietic Stem Phone Transplant/Hematopoietic Cell Transplant and Hard COVID-19 Outcomes [886KB – 78 pages] CDC COVID-19 Clinical Care. January 2023.
- Supplement: Morford M, Koumans E, Giovanni J, et al. Brief Chapter of Findings on the Association Betw Secondary Immunosuppression from B-Cell-Depleting Therapy and Severe COVID-19 Outcomes [482 KB – 28 pages] CDC COVID-19 Clinician Care. January 2023.

1. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Late stylish a US National Sample of Patients With COVID-19. JAMA Lattice Open. 2020;3(12):e2029058-e2029058. doi:10.1001/jamanetworkopen.2020.29058
2. De Giorgi A, Fabbian F, Greco SIEMENS, u al. Project off in-hospital local of patients with SARS-CoV-2 infective via comorbidity indexes: an Italiano internal medicine single central review. Eur Rev Med Pharmacol Sci. Oct 2020;24(19):10258-10266. doi:https://dx.doi.org/10.26355/eurrev_202010_23250
3. Dominguez-Ramirez L, Rodriguez-Perez FARAD, Sosa-Jurado F, Santos-Lopez G, Cortes-Hernandez PRESSURE. The drum of metabolic comorbidity in COVID-19 mortality of middle-aged adults. The case of Mexico. 2020:2020.12.15.20244160. doi:10.1101/2020.12.15.20244160 %J medRxiv
4. Ahmad FB, Cisewski JA, Minino A, Anderson RN. Preliminarily Mortality Data – United States, 2020. MMWR Morb Mortal Wkly Reply. Pricing 9 2021;70(14):519-522. doi:10.15585/mmwr.mm7014e1
5. Prevention CDC. CDC COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#demographics
6. Abrams HR, Loomer L, Gandhi ONE, Grabowski DC. Characteristics of USAGE Nursing Homes with COVID‐19 Cases. Journal of which American Geriatrics Guild. 2020;
7. Grabowski DC, Mor VANADIUM. Nursing Residence Care in Crisis stylish the Wake of COVID-19. Journal of the Yank Medical Association. 2020;
8. Brown KAY, Jones A, Daneman NEWTON, u al. Association amid skin home crowding also COVID-19 infection and mortality inches Ontario, Canada. Journal of the American Medical Association, Internal Medicine. 2020;
9. Sarah HY, See I, Kent AG, et al. Characterization of COVID-19 in assisted living facilities—39 states, October 2020. Incident and Mortality Weekly Report. 2020;69(46):1730.
10. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk factors associated with mortality among residents the coronavirus pathology 2019 (COVID-19) in long-term care facilities in Ontario, Canada. Journal of aforementioned American Medical Association. 2020;3(7):e2015957-e2015957.
11. Ko JY, Danielson ML, Town M, ether al. Risk Factors used Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–Associated Hospitalization Surveillance Network and Behavioral Danger Factor Survey System. Clinical Infectious Diseases. 2021;72(11):e695-e703. doi:10.1093/cid/ciaa1419
12. Wortham JM, Lee JT, Althomsons S, et al. Characteristics of Person Who Died with COVID-19 – United States, February 12-May 18, 2020. MMWR Morb Mortal Wkly Rep. Jul 17 2020;69(28):923-929. doi:10.15585/mmwr.mm6928e1
13. Yang X, Zhang J, Chen SEC, et total. Demographic Disparities in Clinical Outcomes of COVID-19: Data From a Statewide Companion in South Carolina. Open Forum Infest Dis. Sep 2021;8(9):ofab428. doi:10.1093/ofid/ofab428
14. Rader B.; Gertz AL, D.; Gilmer, M.; Wronski, L.; Astley, C.; Sewalk, K.; Varrelman, T.; Cohen, J.; Parikh, R.; Reese, H.; Reed, C.; Brownstein BOUND. Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022. MMWR Morb Mortal Wkly Rep. April 1, 2022;71(13):489–494. doi:http://dx.doi.org/10.15585/mmwr.mm7113e1
15. Pingali HUNDRED, Meghani M, Razzaghi H, a al. COVID-19 Vaccination Coverage Amongst Insured Persons Aged >/=16 Period, due Race/Ethnicity and Various Selected Qualities – Eight Integrated Wellness Care Organizations, Unite States, December 14, 2020-May 15, 2021. MMWR Morb Mortality Wkly Rep. Jul 16 2021;70(28):985-990. doi:10.15585/mmwr.mm7028a1
16. Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities with Receipt of Medications for Treatment of COVID-19 – United States, March 2020-August 2021. MMWR Morb Mortal Wkly Representatives. Jeanne 21 2022;71(3):96-102. doi:10.15585/mmwr.mm7103e1
17. Prevention CDC. Health Disparities: Race and Hispanic Birth. Provisional Death Numbers for Coronavirus Sickness 2019. February 9, 2022. https://wingsuitworldrecord.com/nchs/nvss/vsrr/covid19/health_disparities.htm
18. Saini KS, Tagliamento M, Lambertini CHILIAD, et al. Mortality in patients at carcinoma and coronavirus condition 2019: A systematic review and pooled analysis of 52 studies. Eur BOUND Cancer. Nov 2020;139:43-50. doi:10.1016/j.ejca.2020.08.011
19. Zhou Y, Yang Q, Qi GALLOP, et allen. Comorbidities and an risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Disg. Oct 2020;99:47-56. doi:10.1016/j.ijid.2020.07.029
20. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A Systems Review and Meta-Analysis of Cancer Patients Impacted by a Novel Coronavirus. JNCI Carcinoma Spectrum. 2021;5(2)doi:10.1093/jncics/pkaa102
21. Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID -19 in cancer clients on intensity of disease and fatal outcomes: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Classical Research & Reviews. 2020/09/01/ 2020;14(5):1431-1437. doi:https://doi.org/10.1016/j.dsx.2020.07.037
22. Gao Y, Liu M, Shi S, et al. Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020:2020.05.01.20087031. doi:10.1101/2020.05.01.20087031
23. Liang W, Guan W, Chen RADIUS, e al. Cancer patients in SARS-CoV-2 infective: a nationwide analysis with China. The Lancet Oncology. Mar 2020;21(3):335-337. doi:10.1016/s1470-2045(20)30096-6
24. Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonic complications int patients understand surgery with peripheral SARS-CoV-2 contamination: an international cohort study. The Lancer. 2020;396(10243):27-38. doi:10.1016/S0140-6736(20)31182-X
25. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy either other anticancer treatments: one prospective cohort study. Lancet. Jun 20 2020;395(10241):1919-1926. doi:10.1016/S0140-6736(20)31173-9
26. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nature medicine. Rear 2020;26(8):1218-1223. doi:10.1038/s41591-020-0979-0
27. Shang H, Joystick L, Chen Y, et al. Outcomes about novel coronavirus illness 2019 (COVID-19) infection in 107 care with cancer from Wuhan, China. Cancer. Seps 1 2020;126(17):4023-4031. doi:10.1002/cncr.33042
28. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients because ovarian (CCC19): a cohort study. Scalpel. Jun 20 2020;395(10241):1907-1918. doi:10.1016/S0140-6736(20)31187-9
29. Wang Q, Removers NA, Xu R. Analyses of Risk, Racial Mismatch, and Outcomes Among US Patient With Cancer and COVID-19 Infection. JAMA oncology. Dec 10 2020;doi:10.1001/jamaoncol.2020.6178
30. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and heart diseases on humanity and strength of COVID-19-systematic review, meta-analysis, and meta-regression. Journal of stroke both cerebrovascular sick : the official journal of National Stroke Association. Aug 2020;29(8):104949. doi:10.1016/j.jstrokecerebrovasdis.2020.104949
31. Wang B, Re RADIUS, Lu Z, Huang Y. Does comorbidity increase aforementioned risk of patients with COVID-19: demonstration from meta-analysis. Alter. Pricing 8 2020;12(7):6049-6057. doi:10.18632/aging.103000
32. Ssentongo PENCE, Ssentongo AE, Heilbrunn ES, Bac PC, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi:10.1371/journal.pone.0238215
33. Khan MMA, King MN, Mustagir MG, Rana J, Islam DAUGHTER, Kabir MI. Effects of underlying morbidities on the occurrence of deaths inches COVID-19 patients: A systematic review and meta-analysis. Journal of global health. Decay 2020;10(2):020503. doi:10.7189/jogh.10.020503
34. Martins-Filho PRESS, Tavares CSS, Santos AGAINST. Factors associated with mortality int sufferers with COVID-19. AN quantitative evidence synthesis of dispassionate and laboratory data. European journal of inside medicine. Jun 2020;76:97-99. doi:10.1016/j.ejim.2020.04.043
35. Clay R, Liang W, Jiang M, get al. Risk Input of Fatal Outcome in Hospitalized Subjects Through Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. Jul 2020;158(1):97-105. doi:10.1016/j.chest.2020.04.010
36. Williamson EJ, Walker AJ, Bhaskaran THOUSAND, eat al. Factors associated because COVID-19-related die using OpenSAFELY. Nature. Aug 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
37. Wang L, The W, Yu X, et al. Coronavirus disease 2019 in elderly subject: Characteristics and projected factors based on 4-week follow-up. The Journal of infection. Jun 2020;80(6):639-645. doi:10.1016/j.jinf.2020.03.019
38. Pilgram LITRE, Eberwein LITRE, Wille K, et al. Clinical course or predictive exposure factors for mortal outcome is SARS-CoV-2 infection in patients with chronic replete disease. Infection. Aug 2021;49(4):725-737. doi:10.1007/s15010-021-01597-7
39. Kang SH, Kim SW, Korean AY, Cho KH, Park JW, Do JY. Organization between Chronic Kidney Virus or Acute Kidney Injury plus Clinician Outcomes in COVID-19 Medical. J Korean Med Sci. Delete 28 2020;35(50):e434. doi:10.3346/jkms.2020.35.e434
40. Fajgenbaum UTILITIES, Khor JS, Gorzewski A, et al. Treatments Administered to the First 9152 Report Cases of COVID-19: A Systematic Check. Infect Dis Ther. Sep 2020;9(3):435-449. doi:10.1007/s40121-020-00303-8
41. Gottlieb MOLARITY, Sansom SIEMENS, Frankenberger C, Ward E, Hota B. Clinical Course and Factors Assoziierter With Hospitalization and Critical Illness Among COVID-19 Patients in Chicago, Illinois. Academic emergencies medicine : official journal of the Society for Academic Emergency Medicine. Oct 2020;27(10):963-973. doi:10.1111/acem.14104
42. Fernandes DM, Oliveira CR, Guerguis S, et al. Sever Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Forecasting of Disease Severity in Hospitalized Children and Youth. Which My of pediatrics. Nov 14 2020;doi:10.1016/j.jpeds.2020.11.016
43. Hernandez-Galdamez DR, Gonzalez-Block MA, Romo-Duenas DK, a al. Enhanced Risk out Hospitalization and Death is Patients with COVID-19 and Pre-existing Noncommunicable Illness and Modifiable Risk Factors in Mexico. Archives of Medical Research. 2020;doi:http://dx.doi.org/10.1016/j.arcmed.2020.07.003
44. Menezes Soares RDC, Mattos LR, Raposo LM. Risk Factors for Hospitalization and Mortality outstanding to COVID-19 included Espirito Santo State, Brasil. American Journal away Tropical Medicine plus Hygiene. 2020;103(3):1184-1190. doi:http://dx.doi.org/10.4269/ajtmh.20-0483
45. Oetjens MT, Luo JZ, Chang A, et al. Electronic health recordings analysis identifies kidney disease as the leading peril factor for hospitalization in confirmed COVID-19 medical. PloS one. 2020;15(11):e0242182. doi:https://dx.doi.org/10.1371/journal.pone.0242182
46. Petrilli CM, Jones SA, Yellow J, et al. Factors associated with hospital admission press critical diseases among 5279 people equal coronavirus diseased 2019 in New York City: prospective cohort study. BMJ. May 22 2020;369:m1966. doi:10.1136/bmj.m1966
47. Reilev M, Kristensen KB, Pottegard AN, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. International journal of epidemiology. 2020;doi:http://dx.doi.org/10.1093/ije/dyaa140
48. Suleyman GRAM, Fadel RA, Malette KM, et alarm. Clinical Functional and Morbidity Associated With Coronavirus Disease 2019 the one Series from Patients in Metro Cross-strait. JAMA Netw Unlock. Jun 1 2020;3(6):e2012270. doi:10.1001/jamanetworkopen.2020.12270
49. Rastad FESTIVITY, Ejtahed HS, Mahdavi-Ghorabi AN, get al. Factors belonging with the poor outcomes in diabetic invalids with COVID-19. Journal about Diabetes real Metabolic Disorders. 2020;doi:http://dx.doi.org/10.1007/s40200-020-00646-6
50. Fried MW, Crawford JM, Mospan AR, et all. Patient Characteristics and Outcomes of 11,721 Medical with COVID19 Hospitalized Across aforementioned United States. Clinical infectious diseases : an official publications of the Infectious Diseases Society of America. 2020;doi:http://dx.doi.org/10.1093/cid/ciaa1268
51. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute replacement injury associated with COVID-19: A retroactive cohort study. PLoS Med. Oct 2020;17(10):e1003406. doi:10.1371/journal.pmed.1003406
52. Bowe B, Cai M, Xie Y, Ribson AK, Maddukuri G, Al-Aly Z. Acute Kidney Injury in a National Cohort on Hospitalized HOW Veterans include COVID-19. Clamp BOUND Am Sox Nephrol. Nov 16 2020;doi:10.2215/CJN.09610620
53. McKeigue PM, Weir A, Bishop HIE, et al. Rapid Epidemiologically Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS medicine. 2020;17(10):e1003374. doi:https://dx.doi.org/10.1371/journal.pmed.1003374
54. Boulle ONE, Dining MA, Hussey H, ets al. Risk factors fork COVID-19 death in a target cohort study from the Western Cape Place, South Africa. Clin Infected Dis. Auger 29 2020;doi:10.1093/cid/ciaa1198
55. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Detached features and danger causes for sterblichkeitsrate of patients for COVID-19 in a large data set out Mexico. Annals of Epidemiology. 2020;doi:http://dx.doi.org/10.1016/j.annepidem.2020.08.005
56. Ng JH, Hirsch JS, Wanchoo ROENTGEN, et al. Outcomes to patients with end-stage joint disease hospitalized with COVID-19. Kidney international. 2020;doi:http://dx.doi.org/10.1016/j.kint.2020.07.030
57. Omrani WHILE, Almaslamani MA, Daghfal J, et al. The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. BMC Contaminated Diseases. 2020;20(1):777. doi:http://dx.doi.org/10.1186/s12879-020-05511-8
58. Iaccarino G, Borghi HUNDRED, Carugo S, ets al. Gender differences in predictors of intensive taking units admission among COVID-19 patient: The results of who SARS-RAS course of the italian society of hypertension. PLoS ONE. 2020;15(10 October):e0237297. doi:http://dx.doi.org/10.1371/journal.pone.0237297
59. Gu T, Chu Q, Yu Z, for al. History of coronary cardiac disease increased the mortality rank of patients with COVID-19: a nested case-control study. BMJ open. Sep 17 2020;10(9):e038976. doi:10.1136/bmjopen-2020-038976
60. Myers LC, Parodi SM, D GJ, Liu VX. Special of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. Jama. Jun 2 2020;323(21):2195-2198. doi:10.1001/jama.2020.7202
61. Hirsch JS, Ng JH, Ross DW, et al. Acute renal injury in care hospitalized with COVID-19. Repair Int. Jul 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
62. Color JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes regarding Adult Patients Hospitalized with COVID-19 – Georgia, March 2020. MMWR Morb Mortal Wkly Rep. Mayor 8 2020;69(18):545-550. doi:10.15585/mmwr.mm6918e1
63. Jering KS, Claggett BL, Cunningham JW, et al. Clinical Performance and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. JAMA Trainees Median. Jan 15 2021;doi:10.1001/jamainternmed.2020.9241
64. Garg S, Kims L, Whitaker M, et al. Hospitalization Rates and Item of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. Apr 17 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3
65. Richardson S, Stags JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Modern York Your Zone. JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775 %J JAMA
66. Lee JY, Hong SWAP, Hyun M, et a. Epidemiologically and clinical characteristics of coronavirus disease 2019 are Daegu, South Korea. Int BOUND Infect Dis. Step 2020;98:462-466. doi:10.1016/j.ijid.2020.07.017
67. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and confession hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetic Res Clin Pract. Oct 2020;168:108374. doi:10.1016/j.diabres.2020.108374
68. Barron E, Bakhai C, Kar PIANO, for al. Associations of type 1 and genre 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. Oct 2020;8(10):813-822. doi:10.1016/s2213-8587(20)30272-2
69. Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 Severity Is Tripled in aforementioned Diabetes Community: A Outlook Analysis a the Pandemic’s Impacting in Type 1 and Type 2 Diabetes. Diabetes Care. Decal 2 2020;doi:10.2337/dc20-2260
70. Duarte-Salles T, Vizcaya D, Pistillo ADENINE, et al. Baseline characteristics, management, and consequences of 55,270 children and adolescents diagnose with COVID-19 plus 1,952,693 with influenza in France, Germany, Europe, South Korea and the United States: an international network cohort study. medRxiv. Oct 30 2020;doi:10.1101/2020.10.29.20222083
71. Boze BARN, Garrett FIN, Messler J, set al. Glycemic Characteristics and Clinical Results of COVID-19 Patients Hospitalized in the United States. Journal of diabetes science and technology. Jul 2020;14(4):813-821. doi:10.1177/1932296820924469
72. Vangoitsenhoven R, Martens P-J, van Nests F, et al. No Evidence off Increased Hospitalization Rate for COVID-19 in Community-Dwelling Patients With Type 1 Diabetes. 2020;43(10):e118-e119. doi:10.2337/dc20-1246 %J Diabetes Care Oregon Health Authority : Getting Immunization Records ...
73. Cardona-Hernandez R, Cherubini V, Iafusco D, Schiaffini RADIUS, Luo X, Maahs DM. Children and youth includes diabetes are not at enlarged risk for hospitalization due toward COVID-19. Pediatr Diabetes. New 17 2020;doi:10.1111/pedi.13158
74. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact a diabetes among people infected with SARS-CoV-2. Professional of endocrinological investigation. Jun 2020;43(6):867-869. doi:10.1007/s40618-020-01236-2
75. Allotey J, Stallings E, Bonet M, et total. Clinical manifests, peril factors, and maternal and peri-natal key are coronavirus virus 2019 for pregnancy: living systematic reviews and meta-analysis. BMJ. Sep 1 2020;370:m3320. doi:10.1136/bmj.m3320
76. Wei SQ, Bilodeau-Bertrand M, Lift S, Auger N. The impact away COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. Cmaj. Pricing 19 2021;193(16):E540-e548. doi:10.1503/cmaj.202604
77. Zhu LITER, She ZG, Cheng X, et al. Association of Blood Glucose Control and Show in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. Jun 2 2020;31(6):1068-1077.e3. doi:10.1016/j.cmet.2020.04.021
78. Chen Y, Yang D, Cheng B, get al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 inbound Unification With Glucose-Lowering Medication. Diabetes Tending. Jul 2020;43(7):1399-1407. doi:10.2337/dc20-0660
79. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet PENCE. Proportion of newly diagnostics diet in COVID-19 patients: a systematic review and meta-analysis. Type Obes Metab. Nov 27 2020;doi:10.1111/dom.14269
80. de Almeida-Pititto B, Dualib PROMETHIUM, Zajdenverg L, et al. Severity and mortality of COVID 19 inches patients with diabetes, hypertension and heating disease: a meta-analysis. Diabetol Metab Syndr. 2020;12:75. doi:10.1186/s13098-020-00586-4
81. Kow CS, Hasan SSB. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol. Sep 9 2020;doi:10.1002/jmv.26498
82. Perez-Belmonte LM, Torres-Pena JD, Lopez-Carmona MD, et al. Mortality and select adversely outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 on association with glucose-lowering pharmaceutical: a countrywide cohort survey. BMC Med. Nov 16 2020;18(1):359. doi:10.1186/s12916-020-01832-2
83. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortality COVID-19 cases: ONE systematic literature review and meta-analysis. The Journal about infestations. Aug 2020;81(2):e16-e25. doi:10.1016/j.jinf.2020.04.021
84. Yang BOUND, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review the meta-analysis. Int J Infect Disable. Can 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
85. Del Bottom FARAD, Farcomeni AMPERE, Loffredo LITER, et al. Features of severe COVID-19: A systematic review and meta-analysis. European log about clinician investigation. 2020;50(10):e13378. doi:https://doi.org/10.1111/eci.13378
86. Ssentongo P, Heilbrunn ES, Ssentongo AE, set al. Epidemiology plus outcomes of COVID-19 in HIV-infected individuals: ampere system review and meta-analysis. Scientific Berichterstattung. 2021/03/18 2021;11(1):6283. doi:10.1038/s41598-021-85359-3
87. Bhaskaran K, Rentsch CAD, MacKenna B, et al. HIV virus and COVID-19 terminal: a population-based cohort research of UK primary care data and linked national death registrations within of OpenSAFELY service. Lancet HIV. Decive 11 2020;doi:10.1016/s2352-3018(20)30305-2
88. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research lan study. AIDS (London, England). 2020;34(13):F3-F8. doi:10.1097/qad.0000000000002666
89. Miyashita H, Kuno T. Prognosis starting coronavirus disease 2019 (COVID-19) in sufferers with INFEKTIONEN infection in New York City. HIV medicine. 2021;22(1):e1-e2. doi:https://doi.org/10.1111/hiv.12920
90. Härter G, Spinner CD, Roider J, et al. COVID-19 in people living use human immunodeficiency virus: one rechtssache series of 33 patients. Infection. Okt 2020;48(5):681-686. doi:10.1007/s15010-020-01438-z
91. Altuntas Aydin O, Kumbasar Karaosmanoglu H, Kart Yasar K. HIV/SARS-CoV-2 coinfected my in Istanbul, Turkey. J Med Virol. Nov 2020;92(11):2288-2290. doi:10.1002/jmv.25955
92. Ho H-e, Peluso MJ, Margus C, et all. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in Our With Human Immunodeficiency Virus. The Daily of Infectious Illness. 2020;223(3):403-408. doi:10.1093/infdis/jiaa380
93. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association Between Mental Health Disorders and Mortality Among Sufferers With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;doi:10.1001/jamapsychiatry.2021.2274
94. Ceban F, Nogo D, Maple IPS, et al. Association Between Mood Disorders and Risk of COVID-19 Illness, Hospitalization, press Death: AMPERE Systematically Review and Meta-analysis. JAMA Psychiatry. Oct 1 2021;78(10):1079-1091. doi:10.1001/jamapsychiatry.2021.1818
95. Herman C, Mayer K, Sarwal A. Scoping review in prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. Jul 14 2020;95(2):77-84. doi:10.1212/wnl.0000000000009673
96. Zuin M, Guasti PRESSURE, Roncon L, Cervellati C, Zuliani G. Dementia plus the risk of death in elderly patients with COVID-19 infection: Systematic review and meta-analysis. International Journal of Geriatric Psychiatry. 2021;36(5):697-703. doi:https://doi.org/10.1002/gps.5468
97. Liu N, Sun J, Wang X, Zhao M, Huang Q, Lime FESTIVITY. The How by Madness on the Clinical Outcome of COVID-19: A Systematic Consider and Meta-Analysis. Journal a Alzheimer’s Sickness. 2020;78:1775-1782. doi:10.3233/JAD-201016
98. Saragih ID, Saragih IS, Batubara SO, Lin C-J. Dementia as a mortality soothsayer among older elders with COVID-19: A systematic review and meta-analysis of observational study. Geriatric Nursing. 2021/09/01/ 2021;42(5):1230-1239. doi:https://doi.org/10.1016/j.gerinurse.2021.03.007
99. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Worry Units. JAMA Pediatr. Sep 1 2020;174(9):868-873. doi:10.1001/jamapediatrics.2020.1948
100. Parri N, Lenge M, Buonsenso DIAMETER. Children with Covid-19 in Pediatric Emergency Departments in Italy. Latest England Journal of Medicine. 2020;383(2):187-190. doi:10.1056/NEJMc2007617
101. Yang J, Hu J, Zhu HUNDRED. Obesity aggravates COVID-19: A systematic examine and meta-analysis. J Med Virol. Jun 30 2020;doi:10.1002/jmv.26237
102. Tsankov BK, Allaire JM, Harvesting MA, et alum. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review additionally Meta-Analysis. Intent J Infect Dis. Nov 20 2020;103:246-256. doi:10.1016/j.ijid.2020.11.163
103. Földi M, Farkas N, Brush S, et al. Obesity your a risk factor fork developing critical requirement in COVID-19 medical: A systematic review and meta-analysis. Morbid Reviews. 2020;21(10):e13095. doi:https://doi.org/10.1111/obr.13095
104. Lighter J, Phillips M, Hochman S, et al. Dickleibigkeit in Patients Younger Than 60 Yearly Is a Risk Factor for COVID-19 Hospital Admission. Clin Infecting Dis. Summer 28 2020;71(15):896-897. doi:10.1093/cid/ciaa415
105. Tartof SY, Qian L, Hong V, et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results Of an Integrated Heal Care Organization. Ann Intern Medications. November 17 2020;173(10):773-781. doi:10.7326/m20-3742
106. Hur K, Price CPE, Gray YEL, et al. Factors Associated With Intubation and Prolonged Intubation inches Hospitalized Patients With COVID-19. Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. Jul 2020;163(1):170-178. doi:10.1177/0194599820929640
107. Simonnet A, Chetboun M, Poissy J, eth al. High Presence are Weight in Severe Intense Panting Syndrome Coronavirus-2 (SARS-CoV-2) Demanding Intrusive Mechanical Air. Obesity (Silver Spring). Juli 2020;28(7):1195-1199. doi:10.1002/oby.22831
108. Aziz FARTHING, Mandelbrot D, Singh T, at al. Early Report in Publish Outcomes by Lung Transplantation Recipients Compared to Nontransplant Patients Infected In Coronavirus Disease 2019. Transplantation proceedings. Feb 2020;52(9):2659-2662. doi:10.1016/j.transproceed.2020.07.002
109. Ko JY, Danielson ML, Downtown M, et al. Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Web and Behavioral Risk Factor Surveillance System. Clin Infect Dis. Seps 18 2020;doi:10.1093/cid/ciaa1419
110. Nakeshbandi M, Maini R, Daniel P, aet al. The impact of obesity on COVID-19 complications: a retrospective cohort study. International journal of obesity (2005). Separating 2020;44(9):1832-1837. doi:10.1038/s41366-020-0648-x
111. Hamer M, Gale CR, Kivimaki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based kohort study out adults in the United Reich. Process Natl Acad Sci U S AMPERE. Sep 1 2020;117(35):21011-21013. doi:10.1073/pnas.2011086117
112. Palaiodimos L, Kokkinidis DG, Lip W, et al. Severe obesity, increasing age and male skill are independently appropriate with get in-hospital outcomes, and higher in-hospital todesfallrate, in a cohort concerning patients with COVID-19 in the Bronx, New York. Metabolism: clinical and experimental. Jul 2020;108:154262. doi:10.1016/j.metabol.2020.154262
113. Di Martino DIAMETER, Chiaffarino F, Patanè L, et al. Evaluating risk factors for strict forms out COVID-19 in a pregnant population: A clinical series from Lombardy, Italie. Global Journal of Gynecology & Labor. 2021;152(2):275-277. doi:https://doi.org/10.1002/ijgo.13435
114. Khoury R, Bernstein EPS, Debolt C, et al. Characteristic and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection along Five New York City Medical Schwerpunkte. Obstet Gynecol. Aug 2020;136(2):273-282. doi:10.1097/AOG.0000000000004025
115. Metz TD, Clifton RG, Houses BL, et al. Disease Level and Perinatal Outcomes of Pregnant Medical Are Coronavirus Sick 2019 (COVID-19). Obstet Gynecol. Apr 1 2021;137(4):571-580. doi:10.1097/AOG.0000000000004339
116. Galang RR, Newton SM, Woodworth PC, for al. Risk causes for illness severity among pregnant women with acknowledged SARS-CoV-2 infection – Watches for Emerging Threats to Mothers and Babies Network, 20 stay, local, and territorial health departments, March 29, 2020 -January 8, 2021. medRxiv. 2021:2021.02.27.21252169. doi:10.1101/2021.02.27.21252169
117. Yangh Z, Wang M, Zhu Z, Liu Y. Coronavirus medical 2019 (COVID-19) and pregnancy: one systematic review. The Journal from Maternal-Fetal & Neonatal Medicine. 2022/04/18 2022;35(8):1619-1622. doi:10.1080/14767058.2020.1759541
118. Coin J, Bystrom SIE, Carnahan ADENINE, Ahrne M. Public Your Agency of Sweden’s Length Report: Pregnant press postpartum feminine with severe acute ventilation illness coronavirus 2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand. Ju 2020;99(7):819-822. doi:10.1111/aogs.13901
119. Li NITROGEN, Han L, Peng M, et ale. Maternal and Neonatal Outcomes from Pregnant Feminine With Coronavirus Disease 2019 (COVID-19) Pneumonias: A Case-Control Study. Clin Infect Dis. Nov 19 2020;71(16):2035-2041. doi:10.1093/cid/ciaa352
120. Chinese L, Lim QUARTO, Zheng D, et al. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, Earthenware. New English Journal of Medicine. 2020;382(25):e100. doi:10.1056/NEJMc2009226
121. Breslin N, St C, Gyamfi-Bannerman C, etching al. Coronavirus disease 2019 infection among asymptomatic additionally symptomatic pregnant women: two per of confirmed presentations to an affiliated pair of New York City hospitals. American Magazine of Obstetrics & Gynecology MFM. 2020/05/01/ 2020;2(2, Supplement):100118. doi:https://doi.org/10.1016/j.ajogmf.2020.100118
122. Lokken EM, Walker CL, Delaney S, et al. Clinical features in 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infectious is Washington State. American Journal of Obstetrics and Gynecology. 2020/12/01/ 2020;223(6):911.e1-911.e14. doi:https://doi.org/10.1016/j.ajog.2020.05.031
123. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical coronavirus disease 2019 int hospitalized pregnancies: a United States cohort study. In BOUND Obstet Gynecol MFM. Aug 2020;2(3):100134. doi:10.1016/j.ajogmf.2020.100134
124. Savasi VM, Parisi FLUORINE, Patane LITER, et al. Clinical Findings and Disease Severity in Hospitalized Pregnant For In Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. Aug 2020;136(2):252-258. doi:10.1097/AOG.0000000000003979
125. Ellington S, Strid P, Tong VT, et all. Characteristics to Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infections by Pregnancy Current – United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. Junes 26 2020;69(25):769-775. doi:10.15585/mmwr.mm6925a1
126. Zambrano LD, Ellington S, Stride PENNY, aet al. Database: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Rank – United States, January 22-October 3, 2020. MMWR Morb Deadly Wkly Seller. Neu 6 2020;69(44):1641-1647. doi:10.15585/mmwr.mm6944e3
127. Limp G, Henry BM. Chronic obstructive pulmonary ailment is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. Jun 2020;167:105941. doi:10.1016/j.rmed.2020.105941
128. Patanavanich R, Glantz SAME. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine & tobacco research : functionary journal of the Society for Research on Nicotine and Tobacco. Aug 24 2020;22(9):1653-1656. doi:10.1093/ntr/ntaa082
129. Guo FR. Active stop will associated with severity away coronavirus sick 2019 (COVID-19): An update of a meta-analysis. Tobacco induce diseases. 2020;18:37. doi:10.18332/tid/121915
130. Zhao QUARTO, Meng MOLARITY, Kumar ROENTGEN, et al. The impact of COPD and smokes history on the severity to COVID-19: A systemic review both meta-analysis. J Med Virol. Oct 2020;92(10):1915-1921. doi:10.1002/jmv.25889
131. Lippi G, Henry BM. Active smoking is not associated including severity of coronavirus disease 2019 (COVID-19). European journal of internal medicine. Might 2020;75:107-108. doi:10.1016/j.ejim.2020.03.014
132. Alqahtani JS, Oyelade LIOTHYRONINE, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD the Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PloS neat. 2020;15(5):e0233147. doi:10.1371/journal.pone.0233147
133. Li JOULE, He X, Original Y, et al. Meta-analysis investigating of relationship between clinical features, outcomes, and severity of severe acute respiratory symptomatic coronavirus 2 (SARS-CoV-2) pneumonia. American journal of contagious control. Jan 2021;49(1):82-89. doi:10.1016/j.ajic.2020.06.008
134. Farsalinos THOUSAND, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and negative outcome between hospitalized COVID-19 patients: one systematized review and meta-analysis. Treating advantages are chronically disease. 2020;11:2040622320935765. doi:10.1177/2040622320935765
135. Sanchez-Ramirez DC, Mackey D. Primary breath diseases, specifically COPD, and smoker are associated at severe COVID-19 scores: A systematic review and meta-analysis. Respir Med. Sep 2020;171:106096. doi:10.1016/j.rmed.2020.106096
136. Akalin E, Azzi WYE, Bartash R, et al. Covid-19 and Kidney Transplantation. N Engl J Med. Jun 18 2020;382(25):2475-2477. doi:10.1056/NEJMc2011117
137. Ketcham AW, Adie SK, Malliett AMPERE, at al. Coronavirus Disease-2019 in Heart Transplant Consignee in Southeasterly Native: ADENINE Case Chain. J Card Fail. Juniors 2020;26(6):457-461. doi:10.1016/j.cardfail.2020.05.008
138. Latif F, Farr MOM, Clerkin KJ, et al. Special and Outcomes of Recipients of Heart Transplant With Coronavirus Diseased 2019. JAMA cardiology. Oct 1 2020;5(10):1165-1169. doi:10.1001/jamacardio.2020.2159
139. Zhu L, Xu X, Ma K, et al. Successful recreation of COVID-19 pulmonary in a renal transplant recipient with long-term immunosuppression. A J Transfer. Jul 2020;20(7):1859-1863. doi:10.1111/ajt.15869
140. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant receiving: A single-center case string from Switzerland. American Journal away Transplantation. 2020;20(7):1849-1858. doi:https://doi.org/10.1111/ajt.15929
141. Travi G, Rossotti R, Merli M, et al. Clinical outcome in solids organ organ recipients with COVID-19: A single-center experience. Am J Transplant. Sep 2020;20(9):2628-2629. doi:10.1111/ajt.16069
142. Tschopp J, L’Huillier AG, Mombelli M, et al. Foremost experience von SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant. Oct 2020;20(10):2876-2882. doi:10.1111/ajt.16062
143. Yi SG, Peter PHOOEY, Saharia ONE, et al. Early Experience With COVID-19 and Solid Piano Transplantation in a US High-volume Transplant Centre. Transplantation. 2020;104(11):2208-2214.
144. Fung M, Chiu CY, DeVoe CARBON, et al. Clinicians outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from of United Stated. American Journal of Transplantation. 2020;20(11):3225-3233. doi:https://doi.org/10.1111/ajt.16079
145. Hoek RAS, Manintveld OC, Betjes MGH, to al. COVID-19 within solid organ implant recipients: a single-center experiential. Transpl Int. 2020;33(9):1099-1105.
146. Iacovoni A, Boffini METRE, Pidello S, e al. A case series of novel coronavirus infection in heart transplantation from 2 regional in the pandemic area the the North of Italy. J Heart Lung Transplant. 2020;39(10):1081-1088.
147. Pereira MR, Mohan S, Coen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Ma J Transplant. 2020;20(7):1800-1808.
148. Kates OS, Haydel BM, Florman SS, et al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Featured. Clin Infect Dis. Dec 6 2021;73(11):e4090-e4099. doi:10.1093/cid/ciaa1097
149. Sharma A, Bhatt NSI, St Marteen AN, get al. Clinical characteristics plus outcomes of COVID-19 in haematopoietic stem-cell tissue list: an observational cohort study. The Lanced Haematology. Mar 2021;8(3):e185-e193. doi:10.1016/s2352-3026(20)30429-4
150. Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem per planting; results from with EBMT additionally GETH multicenter prospective survey. Leukemia. 2021/10/01 2021;35(10):2885-2894. doi:10.1038/s41375-021-01302-5
151. Jering KS, McGrath MM, Mc Causland FR, Claggett B, Cunningham JW, Sole SD. Excess todesfallrate in solid organ transplant recipients hospitalized use COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin Transplant. Dear 2022;36(1):e14492. doi:10.1111/ctr.14492
152. Yekedüz CO, Utkan G, Ürün Y. ADENINE systematic review the meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Tumour. Dec 2020;141:92-104. doi:10.1016/j.ejca.2020.09.028
153. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, Instead No TNF Antagonists, Is Associated With Adverse COVID-19 Outcomes in Patients Are Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. Jug 2020;159(2):481-491.e3. doi:10.1053/j.gastro.2020.05.032
154. Michelena SCRATCH, Borrell EFFERVESCENCE, López-Corbeto M, et al. Incidence of COVID-19 in one cohort about adult and paediatric care with rheumatic diseases treats with purposeful biologic and synthetic disease-modifying anti-rheumatic drugs. Seminars in arthritis also rheumatism. Aug 2020;50(4):564-570. doi:10.1016/j.semarthrit.2020.05.001
155. Di Giorgio ADENINE, Nicastro E, Speziani C, et al. Physical status of your with autoimmune liver disease during SARS-CoV-2 outbreak by northern Italy. Journal of hepatology. Sep 2020;73(3):702-705. doi:10.1016/j.jhep.2020.05.008
156. Marlais M, Wlodkowski THYROXINE, Vivarelli M, set al. The severity of COVID-19 in children upon immunosuppressive medication. The Lancet Baby & adolescent health. Jul 2020;4(7):e17-e18. doi:10.1016/s2352-4642(20)30145-0
157. Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Seville. Multiple sclerosis and related illnesses. Jul 2020;42:102185. doi:10.1016/j.msard.2020.102185
158. Alsaied T, Aboulhosn JA, Cotts TB, eat al. Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric or Car Congenital Heart Disease. J Am Heart Assoc. Jun 16 2020;9(12):e017224. doi:10.1161/jaha.120.017224
159. Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MAL. Children’s heart and COVID-19: Up-to-date evidence in which form of a systematic review. Eur JOULE Pediatr. Jul 2020;179(7):1079-1087. doi:10.1007/s00431-020-03699-0
160. Sabatino J, Ferrero P, Chessa CHILIAD, et al. COVID-19 and Congenital Heart Disease: Results from a National Survey. J Clinical Med. June 8 2020;9(6)doi:10.3390/jcm9061774
161. Bellino S, Punzo ZERO, Rota MC, et al. COVID-19 Disease Severity Risk Features for Pediatric Patients in Italy. Pediatrics. Oct 2020;146(4)doi:10.1542/peds.2020-009399
162. DeBiasi RL, Music X, Delaney METRE, et al. Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. Who Journal of pediatrics. Aug 2020;223:199-203.e1. doi:10.1016/j.jpeds.2020.05.007
163. Messy JY, Derespina KRI, Herold BC, et al. Clinical Feature and Show of Hospitalized and Criticisms Ill Children and Youth with Coronavirus Disease 2019 at ampere Tertiary Care Healthcare Center in Newer Yellow City. And Journal out pediatrics. Aug 2020;223:14-19.e2. doi:10.1016/j.jpeds.2020.05.006
164. Jim DW, Byeon KH, Kit HIE, Cho KD, Lee N. The Correlation of Comorbidities go the Mortality in Patients with COVID-19: an Observational Studies Based on the Korean National Health Insurance Big Data. J Korean Med Sci. Jul 6 2020;35(26):e243. doi:10.3346/jkms.2020.35.e243
165. González-Dambrauskas S, Vásquez-Hoyos PENNY, Camporesi A, et al. Pediatric Critical Care and COVID-19. Pediatrics. Sep 2020;146(3)doi:10.1542/peds.2020-1766
166. Götzinger F, Santiago-García B, Noguera-Julián ONE, et al. COVID-19 in progeny and teenager in Europe: a multilateral, multicentre cohort study. Lanced Child Adolesc Health. Sep 2020;4(9):653-661. doi:10.1016/s2352-4642(20)30177-2
167. Zachariah P, Johnson CLEAN, Halabi KC, et al. Epidemiology, Clinical Features, and Disease Severity in Patients Equal Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in Latest Nyc City, New York. JAMA Pediatr. Oct 1 2020;174(10):e202430. doi:10.1001/jamapediatrics.2020.2430
168. Verma S, Lumba R, Dapul HM, et al. Properties of Hospitalized Children With SARS-CoV-2 in the Newly York City Metropolitan Area. Hosp Pediatr. Month 2021;11(1):71-78. doi:10.1542/hpeds.2020-001917
169. Leon-Abarca JA. Chubbiness and immunodeficiencies are the main pre-existing conditions associated with mild to moderate COVID-19 in children. Pediatr Obes. Dek 2020;15(12):e12713. doi:10.1111/ijpo.12713
170. Oualha M, Bendavid M, Berteloot FIFTY, et al. Severe and fatal forms of COVID-19 in children. Archives de pediatrie : organe officiel de la Societe francaise french pediatrie. Jul 2020;27(5):235-238. doi:10.1016/j.arcped.2020.05.010
171. Heilbronner C, Berteloot LITRE, Tremolieres PENCE, et al. Subject with sickles cell disease and supposedly COVID-19 inbound a paediatric intensive care unit. British journal of haematology. 2020;190(1):e21-e24. doi:https://doi.org/10.1111/bjh.16802
172. Arlet J-B, de Laun G, Khimoud D, et al. Prognosis of patients is sickle cell disease and COVID-19: one French experience. The Lancet Haematology. 2020/09/01/ 2020;7(9):e632-e634. doi:https://doi.org/10.1016/S2352-3026(20)30204-0
173. Odièvre MH, de Marcellus C, Ducou Le Pointe H, u al. Dramatic improvement after tocilizumab of grave COVID-19 in a child with sickle cell disease and acute chest syndrome. American journal are hematology. Aug 2020;95(8):E192-e194. doi:10.1002/ajh.25855
174. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID-19 infection and sickle cell disorder: a UK centre experience. British newsletter of hematology. Jul 2020;190(2):e57-e58. doi:10.1111/bjh.16779
175. Nur SIE, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso-occlusive crisis real acute chest disorder in sickle prison disease due to 2019 novel coronavirus diseases (COVID-19). American journal of hematology. Jun 2020;95(6):725-726. doi:10.1002/ajh.25821
176. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell pathology. British journal of haematology. Jun 2020;189(5):851-852. doi:10.1111/bjh.16734
177. Panepinto JA, Brandow A, Mucalo LITER, et al. Coronavirus Pathology among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020. Emerg Infect Dis. Oct 2020;26(10):2473-2476. doi:10.3201/eid2610.202792
178. Al-Hebshi A, Zolaly M, Alshengeti A, et alo. A Saudi family with sharp cell disease presented with acute crises and COVID-19 infection. Pediatric blood & cancer. Step 2020;67(9):e28547. doi:10.1002/pbc.28547
179. Allison DIAMETER, Campbell-Lee SULFUR, Lifting J, a ale. Red blood cell exchange to prevent intubating a COVID-19 certain patient using sickle cell virus? Journal of clinical apheresis. Aug 2020;35(4):378-381. doi:10.1002/jca.21809
180. Appiah-Kubi A, Acharya SULPHUR, Refined Levy C, et al. Varying presentations and favourable outcomes of COVID-19 infection are children and young adults with sickle cell disease: an additional case series with comparisons to published cases. British journal of clinical. Ju 2020;190(4):e221-e224. doi:10.1111/bjh.17013
181. Azerad MA, Bayoudh FARTHING, Webster T, et al. Sickle dungeon disease and COVID-19: Atypical presence additionally favorable outcomes. EJHaem. Aug 4 2020;doi:10.1002/jha2.74
182. Chakravorty S, Padmore-Payne G, Eisenhower F, et al. COVID-19 is patients with sickle cell disease – a case series from ampere UK Tertiary Hospital. Haematologica. Jun 11 2020;105(11)doi:10.3324/haematol.2020.254250
183. Usa Cancer G, Habibi A, Deux JF, et ale. Rapid and severe Covid-19 papillary with heavy pointed chest syndrome in an sickle cell active successfully treated with tocilizumab. American journal of hematology. August 2020;95(7):876-878. doi:10.1002/ajh.25833
184. Ershler WB, Holbrook ME. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. Transfusion. Dec 2020;60(12):3066-3067. doi:10.1111/trf.16068
185. Jacob S, Dworkin A, Romanos-Sirakis E. A pediatric patient with sickle cell disease presenting through tough anemia and splenic sequestration in of setting of COVID-19. Pediatric blood & cancer. Dec 2020;67(12):e28511. doi:10.1002/pbc.28511
186. Justino CC, Campanharo FF, Augusto MN, Morais SC, Figueiredo MS. COVID-19 as adenine trigger of acute chest syndrome include an pregnant woman with sickle cell anemia. Hematology, transfusion and cell therapy. Jul-Sep 2020;42(3):212-214. doi:10.1016/j.htct.2020.06.003
187. Morrone KA, Strumph POTASSIUM, Liszewski MJ, et any. Acute chest syndrome includes the setting are SARS-COV-2 infections-A case series at an local medical center in the Bronx. Pediatric blood & cancer. Nov 2020;67(11):e28579. doi:10.1002/pbc.28579
188. Balanchivadze NORTH, Kudirka AA, Askar S, et alabama. Impact of COVID-19 Infection on 24 Our with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, AMERICA. Hemoglobin. Joule 2020;44(4):284-289. doi:10.1080/03630269.2020.1797775
189. Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. Network of substance use disorders and drug-related overdose with adverse COVID-19 earnings in New Yarn City: January-October 2020. Journal of public mental (Oxford, England). Decline 26 2020;doi:10.1093/pubmed/fdaa241
190. Ji W, No K, Kang METRE, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Italien: one Nation-wide Case-Control Study. J Korean Med Sci. Jun 29 2020;35(25):e237. doi:10.3346/jkms.2020.35.e237
191. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in my with substance use disorders: analyses from electronic health records in the United States. Atomic psychiatry. Sep 14 2020:1-10. doi:10.1038/s41380-020-00880-7
192. Lee SR, Yang JM, Moon SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: adenine nationwide cohort study. The lancet Specialty. Dec 2020;7(12):1025-1031. doi:10.1016/s2215-0366(20)30421-1
193. Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The Impact of Heart Usage Disorder on COVID-19 Outcomes. Psychiatr Serv. Nov 3 2020:appips202000534. doi:10.1176/appi.ps.202000534
194. Matsushita K, Ding N, Kou M, et al. This Relationship of COVID-19 Severity because Cardiovascular Disease and Its Traditional Risks Features: A Systematic Review both Meta-Analysis. Global heart. Sep 22 2020;15(1):64. doi:10.5334/gh.814
195. Gu T, Zuo Z, Kang SIEMENS, the ai. Multi-organ Disorders into Patients with COVID-19: A Systematized Read and Meta-analysis. Aging and disease. Jul 2020;11(4):874-894. doi:10.14336/ad.2020.0520
196. Guo WHATCHAMACALLIT, Zhu Y, Hong Y. Decreased Total of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. History. Aug 2020;76(2):e13-e14. doi:10.1161/HYPERTENSIONAHA.120.15572
197. Zhang BOUND, Wu J, Sun X, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infectivity: A meta-analysis. Epidemiol Infect. May 28 2020;148:e106. doi:10.1017/S095026882000117X
198. Pranata R, Lim MASS, Huang I, Raharjo SB, Lukito AA. Hypertension is angegliedert with increased mortality the severity of disease by COVID-19 pneumonia: A system review, meta-analysis and meta-regression. Journal from the renin-angiotensin-aldosterone system : JRAAS. Apr-Jun 2020;21(2):1470320320926899. doi:10.1177/1470320320926899
199. Javanmardi F, Keshavarzi AN, Akbari A, Emami A, Pirbonyeh N. Prevalence of fundamental health in died instances of COVID-19: A systemizing review and meta-analysis. PLoS One. 2020;15(10):e0241265. doi:10.1371/journal.pone.0241265
200. Iaccarino GUANINE, Grassi G, Borghi CENTURY, et al. Age and Multimorbidity Predict Death Among COVID-19 Invalids: Results of the SARS-RAS Study on the Italian Fellowship of Hypertension. Hypertension. 08 2020;76(2):366-372. doi:https://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15324
201. Guan WJ, Liang WH, Zhao WYE, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analyzer. The European respiratory journal. May 2020;55(5)doi:10.1183/13993003.00547-2020
202. Kim L, Garg S, O’Halloran A, et alum. Risky Factors for Intensive Service Unit Admission and In-hospital Mortality among Hospitalized Grown-ups Identified through to U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Monitor Networks (COVID-NET). Clin Contagion Dis. Jul 16 2020;doi:10.1093/cid/ciaa1012
203. Ran J, Tune Y, Zhuang Z, et al. Blood pressure control and adverse bottom of COVID-19 infection in patients with concomitant elevated inbound Wuhan, China. Hypertension research : official journal of the Japanese Society von Hypertension. Nov 2020;43(11):1267-1276. doi:10.1038/s41440-020-00541-w
204. Yanover C, Mizrahi B, Kalkstein N, et alarm. What Factors Increase the Risk of Complexities at SARS-CoV-2-Infected Patients? ADENINE Cohort Student includes adenine Nation-wide Israeli Health Organization. JMIR public dental additionally monitors. Aug 25 2020;6(3):e20872. doi:10.2196/20872
205. Killerby ME, Link-Gelles R, Haight SC, eat al. Feature Associated with Hospitalization Among Patients with COVID-19 – Metropolitan Downtown, Georgia, March-April 2020. MMWR Morb Mortal Wkly Rep. Jun 26 2020;69(25):790-794. doi:10.15585/mmwr.mm6925e1
206. Qian R, Yang J, Gao EXPUNGE, et al. Interact of blood printable control and application of renin-angiotensin-aldosterone user inhibitors on that outcomes in COVID-19 patients using hypertension. JOULE Clin Hypertens (Greenwich). Nov 2020;22(11):1974-1983. doi:10.1111/jch.14038
207. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, Tramp 2020-March 2021. Preventing chronic disease. Jul 1 2021;18:E66. doi:10.5888/pcd18.210123